Sotera Health Company (NASDAQ:SHC) Receives $20.25 Consensus Price Target from Analysts

Sotera Health Company (NASDAQ:SHC) has been given a consensus rating of “Moderate Buy” by the eleven analysts that are presently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $20.25.

Several brokerages have recently issued reports on SHC. Weiss Ratings upgraded shares of Sotera Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, July 9th. Barclays raised their price objective on Sotera Health from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. UBS Group set a $19.00 price objective on Sotera Health in a research report on Wednesday, June 24th. Piper Sandler reaffirmed an “overweight” rating and issued a $22.00 target price (down from $24.00) on shares of Sotera Health in a report on Wednesday, May 6th. Finally, Wall Street Zen lowered Sotera Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 11th.

Sotera Health Trading Down 2.8%

Shares of Sotera Health stock opened at $17.75 on Friday. The firm has a market capitalization of $5.06 billion, a PE ratio of 43.29 and a beta of 1.76. The company has a current ratio of 2.82, a quick ratio of 2.54 and a debt-to-equity ratio of 3.56. The firm’s 50 day moving average is $16.46 and its 200 day moving average is $16.41. Sotera Health has a 1 year low of $10.94 and a 1 year high of $19.85.

Sotera Health (NASDAQ:SHC) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.17 by $0.01. Sotera Health had a net margin of 9.91% and a return on equity of 39.73%. The business had revenue of $280.05 million during the quarter, compared to the consensus estimate of $270.78 million. During the same quarter in the prior year, the firm earned $0.14 EPS. The firm’s revenue was up 10.0% compared to the same quarter last year. Sotera Health has set its FY 2026 guidance at 0.930-1.010 EPS. Equities research analysts forecast that Sotera Health will post 0.87 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $15.17, for a total value of $193,194,516.17. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 15.36% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sotera Health

Institutional investors have recently added to or reduced their stakes in the business. Empowered Funds LLC raised its stake in shares of Sotera Health by 11.1% during the first quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock valued at $332,000 after acquiring an additional 2,845 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Sotera Health by 14.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock worth $3,999,000 after purchasing an additional 43,471 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Sotera Health by 125.5% in the first quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock worth $293,000 after purchasing an additional 14,018 shares during the last quarter. Creative Planning increased its holdings in Sotera Health by 15.3% in the second quarter. Creative Planning now owns 20,186 shares of the company’s stock valued at $224,000 after purchasing an additional 2,673 shares during the period. Finally, Invesco Ltd. increased its holdings in Sotera Health by 4.2% in the second quarter. Invesco Ltd. now owns 319,156 shares of the company’s stock valued at $3,549,000 after purchasing an additional 12,758 shares during the period. 91.03% of the stock is owned by institutional investors.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.